Life Style

FIND announces the launch of a request for proposal to expand access to the COVID-19 test service

The Foundation for Innovative New Diagnostics (FIND) today announced a request for proposal to accelerate the development, manufacture, and market availability of an easy-to-use SARS-CoV-2 with guaranteed accuracy, affordability, and quality. RFP) has been announced. Self-test for use in low and middle income countries (LMIC). As part of a comprehensive testing program, self-managed testing expands access to test services, links to appropriate responses for quarantine, contract tracking, and care, and responds to COVID-19 by reducing community expansion. May change. This RFP was created in the context of access to the pillars of COVID-19 Tool (ACT) Accelerator Diagnostic, jointly organized by FIND and the Global Fund.

The test continues to play an important role in the COVID-19 pandemic, enabling not only patient care, but also providing decision makers with important data on actual vaccine coverage and the emergence of variants. Notify test trace isolation strategy and blockade. Between one-third antigen Rapid testing received the World Health Organization (WHO) Emergency Use List on March 17, 2021. Inspection capabilities are still highly centralized in many countries and are insufficient to meet current demand.

This is especially true for LMIC. In this case, vulnerable healthcare systems and a monopoly reliance on the global supply chain often prevent healthcare providers from accessing urgently needed tests. For all tests conducted in low-income countries, more than 80 tests have been conducted in high-income countries. These problems are the lack of access to the laboratories needed to process more complex molecular tests, and often the rapid consequences of living far away from health centers and avoiding multiple journeys. It arises from a group that needs.

Modeling suggests that frequent tests with rapid turnaround times have a greater impact on infection than one-time tests using more sensitive but slower laboratory-based diagnostics. Such a set of testing strategies may detect individuals with the highest viral load that are most infectious to others, promote early quarantine of infected individuals, and ultimately reduce infection.

Currently, there is no affordable SARS-CoV-2 self-test for use in resource-constrained environments. The US Food and Drug Administration (FDA) has approved five tests for home use, but they are too expensive to be widely adopted by LMIC. However, low-cost technology, initially developed for management by healthcare professionals, can be adapted to affordable self-testing.

Given the high risk of user error in self-testing compared to professionally managed testing, the central focus of the RFP is very easy to use, which may be due to product design. Addressing the availability of self-test solutions (easily available samples, intuitive test interpretations, accessible instructions, etc.) and / or support tools (such as digital solutions).

Suggestions are invited by innovators, in vitro diagnostic (IVD) manufacturers, and LMIC-based diagnostics stakeholders. An initial budget envelope of $ 15 million will be available to support a few proposals that offer the best cost-effectiveness. Financing negotiations are independent for each proposal and are tailored to the needs of the applicant and the details of each business case.

Even if the vaccine becomes available, it is clear that we will live longer with COVID-19, and testing remains important to keep people safe. For other infectious diseases such as HIV, we have seen how self-testing can have a powerful impact on the fight against epidemics. This is an important element of the weapon against COVID-19, allowing people to manage their own health. “

Chief Access Officer and ACT-Accelerator Lead, FIND, Emma Hannay

Even though rapid inspection prices have fallen, only developed countries have expanded inspections, but LMIC still has a large access gap. Most of the tests at LMIC are done only in higher level medical environments and are not tested by the large number of people living in rural areas. There is an urgent need for new use cases for the broad community and self-testing. “

Peter Ngo’la Owiti, Community Representative, ACT-Facilitation Council

Testing is an important tool for fighting COVID-19. We need to make the tests accessible to everyone, from central hospitals to remote communities. Self-administrative testing allows you to monitor and stop the spread of COVID-19 even in areas without testing facilities. Without fair and extended access to testing, the fight against this pandemic would not be successful. “

Peter Sands, Secretary-General of the World Fund

The RFP was started to support the work plans of the two working groups within the ACT-Accelerator Diagnostics Pillar. “R & D of Testing and Digital Tools” (led by Bill & Melinda Gates Foundation and Presence Foundation) and “Market Preparation” (led by Unitaid and FIND), as described in 2021 ACT-Accelerator Strategy and Budget In addition, the pillars of this year’s diagnosis are aimed at:

  • Ensure equitable access to new and existing tests, including the procurement and distribution of at least 900 million molecular and antigen rapid tests (including self-tests)
  • Stimulates the rapid and effective uptake of appropriate and quality-guaranteed diagnostics in the country
  • Drives the development and large-scale availability of innovative, affordable digital integration tests.

The specific activities supported as part of this initiative will depend on the needs of each applicant. For more information on RFPs and how to apply, please visit: www.finddx.org/rfp-covid19-self-tests/ Two Q & A workshops for potential applicants will be held on Monday, April 12, 2021 via Zoom. Please register for the 09:00 CET Workshop. Here, Or 17:00 CET Workshop Here..

FIND announces the launch of a request for proposal to expand access to the COVID-19 test service

Source link FIND announces the launch of a request for proposal to expand access to the COVID-19 test service

Back to top button